Heartbeam Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Heartbeam Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.406 $ to 3.40 $ · Last price: 0.4029 $ (As of: September 18, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Health Information Services
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Heartbeam Inc BEAT | 0.0 | – | -3.0 | – | – | -100.0 | -70.2 |
| Veeva Systems Inc Class A VEEV | 40.5 | 43.4 | 33.4 | 75.0 | 30.9 | 16.3 | -3.9 |
| Tempus AI, Inc. TEM | 13.8 | – | 0.0 | 64.0 | -24.3 | 83.4 | -7.0 |
| BrightSpring Health Services, Inc. BTSG | 11.2 | 73.6 | 22.6 | 12.4 | 3.4 | 14.6 | 106.6 |
| 10X Genomics Inc TXG | 10.1 | – | 148.5 | 70.1 | -11.3 | 5.3 | 498.5 |
| HealthEquity Inc HQY | 7.9 | 39.8 | 16.8 | 71.3 | 29.3 | 9.5 | 2.4 |
| Hinge Health, Inc. HNGE | 7.7 | 11.9 | 71.9 | 84.5 | 19.0 | 50.6 | 66.8 |
| Doximity Inc DOCS | 4.8 | – | 18.7 | 88.1 | 21.6 | 13.1 | -63.4 |
| Waystar Holding Corp. WAY | 4.6 | – | 14.8 | 69.1 | 25.6 | 16.5 | -31.3 |
| Median of companies shown | 7.9 | 41.6 | 18.7 | 70.7 | 20.3 | 14.6 | -3.9 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 208 | 36 | 53 | 1.75 | 39 | 139 | 199 |
| 2017 | 287 | 37 | -16 | -0.53 | 24 | 251 | 525 |
| 2018 | 399 | 84 | 43 | 1.20 | 73 | 310 | 587 |
| 2019 | 439 | 0 | -1 | -0.10 | 0 | -4 | 0 |
| 2020 | 0 | -1 | -1 | -0.17 | -1 | -5 | 0 |
| 2021 | 0 | -2 | -4 | -0.57 | -3 | 13 | 14 |
| 2022 | 0 | -13 | -13 | -1.57 | -10 | 2 | 4 |
| 2023 | 0 | -15 | -15 | -0.72 | -12 | 16 | 17 |
| 2024 | 0 | -20 | -19 | -0.73 | -14 | 2 | 3 |
| 2025 | 0 | -21 | -21 | -0.62 | -14 | 3 | 6 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.18 | – | 0 | – | – | -4 | -4 |
| 2025: Q1 | -0.10 | – | 0 | – | – | -5 | -5 |
| 2025: Q2 | -0.09 | – | 0 | – | – | -3 | -4 |
| 2025: Q3 | -0.09 | – | 0 | – | – | -3 | -3 |
| 2025: Q4 | -0.14 | – | 0 | – | – | -3 | -3 |
| 2026: Q1 | -0.08 | – | 0 | – | – | -4 | -4 |
| 2026: Q2 | -0.10 | -11.10 | – | – | – | -3 | -4 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Downward Momentum
- Insolvency Radar: Cash Running Low
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Weakness Cluster
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.40 | -0.41 – -0.37 | 0 | – | 3 |
| 12/31/2027 | -0.31 | -0.34 – -0.28 | 4 | – | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 588.9%
- Share count grows by less than 3% a year 60.4%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 4 m net cash
- Operating cash flow covers the profits of the last three years 15 m
- Return on capital at 15% or higher, or up versus two years ago -812.1%
- Insiders hold at least 10% or are net buyers 13.9%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 3
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -807.5%
- ROCE > 15% -812.1%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
HeartBeam, Inc. ist ein Medizintechnikunternehmen, das sich auf die Entwicklung und Vermarktung von EKG-Lösungen konzentriert, die die Erkennung und Überwachung von Herzerkrankungen außerhalb medizinischer Einrichtungen ermöglichen.
- Employees
- 16
- Headquarters
- Santa Clara, CA
- Address
- 2118 Walsh Avenue, 95050 Santa Clara, United States
- Phone
- 408 899 4443
- Website
- heartbeam.com
- IPO Date
- 11/11/2021
- ISIN
- US42238H1086
Management
| Name | Title | Birth Year |
|---|---|---|
| Richard M. Ferrari | Executive Chairman | 1954 |
| Branislav Vajdic Ph.D. | Founder, President & Director | 1955 |
| Timothy Cruickshank | Chief Financial Officer | 1982 |
| Kenneth Persen | Chief System Development Officer | – |
| Peter J. Fitzgerald FACC, M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Advisor | 1957 |
| Richa Gujarati | Senior Vice President of Product | – |
| Lance Myers Ph.D. | Chief Artificial Intelligence Scientist | – |
| Bryan Humbarger | Chief Commercial Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.